<DOC>
	<DOC>NCT01421186</DOC>
	<brief_summary>This is an open-label, multicentre, dose escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects with relapsed/refractory multiple myeloma, as monotherapy and in adult subjects with relapsed/refractory multiple myeloma in combination with standard therapy.</brief_summary>
	<brief_title>A Phase I/IIa Study of Human Anti-CD38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1. Male or female subjects 18 years and older 2. Relapsed or refractory multiple myeloma defined as: Parts A, B and C: (i) Failure of at least 2 previous therapies which must have included an immunomodulatory agent and a proteasome inhibitor (either together or part of different therapies) (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma Part D: (i) At least 2 previous therapies including lenalidomide and a proteasome inhibitor (ii) All subjects must have documented progression during or within 60 days after their last prior therapy for multiple myeloma Part E: (i) Received at least one previous therapy (ii) All subjects must have documented progression during or after their last prior therapy for multiple myeloma 3. Presence of serum Mprotein ≥ 0.5 g per 100 mL (≥ 5 g/L) and / or urine Mprotein ≥ 200 mg per 24hour period 4. Absolute neutrophil count (ANC) ≥ 1,000 / mm3 5. Haemoglobin ≥ 8 g/dL 6. Ability to comply with all study related procedures, medication use and evaluations 1. Primary refractory multiple myeloma 2. History of significant cerebrovascular disease or sensory or motor neuropathy of toxicity grade 3 or higher 3. Treatment with systemic investigational agent within 28 days prior to first study treatment 4. Solitary plasmacytoma or plasma cell leukaemia 5. Previous allogenic SCT 6. Prior therapy with other monoclonal antibodies targeting the CD38 antigen or prior therapy with other IgG monoclonal antibodies within 3 months prior to first study treatment, or IgM monoclonal antibodies within 1 month prior to first study treatment 7. Active systemic infection 8. Systemic disease preventing study treatment 9. Multiple myeloma with CNS involvement 10. Previous treatment with cytotoxic chemotherapy or large field radiotherapy or other myeloma specific therapy within 28 days prior to first study treatment (radiation to a single site as concurrent therapy is allowed) 11. Significant uncontrolled cardiovascular disease or cardiac insufficiency (New York Heart Association [NYHA] classes III, IV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>MOR03087 (MOR202)</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>CD38</keyword>
</DOC>